Inhibition of Prostate Cancer Cells by 4, 5-Dicaffeoylquinic Acid through Cell Cycle Arrest. (23rd May 2019)

• Record Type: Journal Article
• Authors: Lodise, Olivia; Patil, Ketki; Karshenboym, Igor; Prombo, Scott; Chukwueke, Chidinma; Pai, S. Balakrishna
• Other Names: Shinohara Katsuto Academic Editor.
• Is Part Of: Prostate cancer. Volume 2019(2019)
• Publication Date: 2019-05-23
• Subjects: Prostate -- Cancer -- Periodicals; Prostate -- Cancer -- Surgery -- Periodicals; 616.99463
• DOI: 10.1155/2019/4520645
• Languages: English
• ISSNs: 2090-3111

Abstract

Abstract : Prostate cancer is a major cause of cancer-related mortality in men. Even though current therapeutic management has contributed to reducing mortality, additional intervention strategies are warranted to further improve the outcomes. To this end, we have investigated the efficacy of dicaffeoylquinic acids, ingredients in Yerba Mate ( Ilex paraguariensis ), an evergreen cultivated in South America, the leaves of which are used to prepare a tea/coffee-like drink. Of the various analogs tested, 4, 5-dicaffeoylquinic acid (4, 5-diCQA) was the most active molecule against DU-145 prostate cancer cells with a 50% inhibitory concentration (IC50 ) of 5 μ M. 4, 5-diCQA was active both under normoxic and hypoxic conditions. The effect of 72-hour treatment on DU-145 cells persisted for an extended time period as assessed by clonogenic assay. Mechanistic studies revealed that the toxic effect was not due to induction of programmed cell death but through cell cycle arrest at S phase. Additionally, 4, 5-diCQA did not impact PI3K/MAPK signaling pathway nor did it affect the depolarization of the mitochondrial membrane. 4, 5-diCQA-induced accumulation of cells in the S-phase also seems to negatively impact Bcl-2 expression. 4, 5-diCQA also exhibited inhibitory activity on LNCaP and PC-3 prostate cancer cells suggesting that it has therapeutic potential on a broad range of prostate cancers. Taken together, the novel inhibitory activity and mechanism of action of 4, 5-diCQA opens up potential therapeutic options for using this molecule as monotherapy as well as in combinatorial therapies for the clinical management of prostate cancer.